Economic consequences of the implementation of primary DNA-HPV genotype testing in Bulgaria

References

• GLOBOCAN. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
   Google Scholar
• Poljak M, Rogovskaya SI, Kesić V, et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer. 2011;31: h80–h82. doi: 10.1016/j.vaccine.2013.04.038.
   Google Scholar
• Arbyn M, Antoine J, Mägi M, et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer. 2011;128:1899–1907.
   PubMed Web of Science ®Google Scholar
• Cervical Cancer: an NCD we can overcome. Geneva: Intercontinental Hotel; 2018 [cited 2023 Mar 1]. Available from: https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf.
   Google Scholar
• WHO. Cervical cancer elimination initiative. Available from: https://www.who.int/initiatives/cervical-cancer-elimination-initiative.
   Google Scholar
• Ki M, Choi HY, Han M, et al. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015. Vaccine. 2018;36(31):4633–4640. doi: 10.1016/j.vaccine.2018.06.046.
   PubMed Web of Science ®Google Scholar
• Gan BK, Macalino GE, Nsouli-Maktabi H, et al. Human papilloma-virus seroprevalence among men entering military service and seroincidence after ten years of service. MSMR. 2013;20(2):21–24.
   Google Scholar
• Hesson HW, Ekwueme DU, Saraiya M, et al. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016–6019. doi: 10.1016/j.vaccine.2012.07.056.
   PubMed Web of Science ®Google Scholar
• Abramowitz L, Lacau Saint Guily J, Moyal-Barracco M, et al. Epidemiological and economic burden of potentially HPV-related cancers in France. PLoS One. 2018;13(9):e0202564. doi: 10.1371/journal.pone.0202564.
   PubMed Web of Science ®Google Scholar
• Östensson E, Silfverschiöld M, Greiff L, et al. The economic burden of human papillomavirus-related precancers and cancers in Sweden. PLoS One. 2017;12(6):e0179520. doi: 10.1371/journal.pone.0179520.
   PubMed Web of Science ®Google Scholar
• Karcheva M, Iordanov A, Tzvetkova S. Current burden of cervical cancer in Bulgaria - epidemiological study. Eur J Public Health. 2020;30(Supplement_5):ckaa166.1091. doi: 10.1093/eurpub/ckaa166.1091.
   Google Scholar
• Yordanov A, Vasileva-Slaveva M, Galai N, et al. Cancer of the cervix in Bulgaria: epidemiology of a crisis. Healthcare (Basel). 2023;11(3):318. doi: 10.3390/healthcare11030318.
   PubMedGoogle Scholar
• European Commission. Europe beating cancer plan; [cited 2023 Mar]. Available from: https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/promoting-our-european-way-life/european-health-union/cancer-plan-europe_en.
   Google Scholar
• National Anticancer Plan. 2030; [cited 2023 Mar]. Available from: https://www.mh.government.bg/media/filer_public/2022/07/08/bg_national_cancer_plan_2030_-_site.pdf.
   Google Scholar
• Wentzensen N, Schiffman M, Palmer T, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76 Suppl 1(Suppl 1):S49–S55. doi: 10.1016/j.jcv.2015.11.015.
   PubMedGoogle Scholar
• WHO recommends DNA testing as a first-choice screening method for cervical cancer prevention; [cited 2023 Mar]. Available from: https://www.who.int/europe/news/item/11-09-2021-who-recommends-dna-testing-as-a-first-choice-screening-method-for-cervical-cancer-prevention#:∼:text=For%20the%20general%20population%20of%20women%2C%20HPV%2DDNA%20detection%20is,screening%20every%203%E2%80%935%20years.
   Google Scholar
• National Cancer Register. 2017; [cited May 2023]. Available from: https://www.sbaloncology.bg/index.php/bg.html.
   Google Scholar
• Kovachev S, Slavov V. Prevalence of human papillomavirus infection in women in Bulgaria: a 2017 update. J Med Virol. 2018;90(6):1142–1149. doi: 10.1002/jmv.25050.
   PubMed Web of Science ®Google Scholar
• Ordinance on terms, rules and procedure for regulation and registration of prices for medicinal products. Adopted in 19 April 2013; last amended and supplemented SG N. 28 of 6 April 2021. https://ncpr.bg/en/regulations/bulgarian-legislation/regulations.html.
   Google Scholar
• National Health Insurance Fund: National Frame Contract 2020–2022; [cited 2023 Feb]. Available from: https://nhif.bg/bg/nrd/2020-2022/medical.
   Google Scholar
• Human Papillomavirus and Related Diseases Report Bulgaria 2023; [cited 2023 Mar]. Available from: https://hpvcentre.net/statistics/reports/BGR.pdf?t=1679479185980.
   Google Scholar
• Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591–603. doi: 10.1016/S0140-6736(20)30157-4.
   PubMed Web of Science ®Google Scholar
• National Statistics Institute; [cited 2019 Feb]. Available from: www.nsi.bg.
   Google Scholar
• Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–197. doi: 10.1016/j.ygyno.2014.11.076.
   PubMed Web of Science ®Google Scholar
• Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive services task force. Ann Intern Med. 2011;155(10):687–697. doi: 10.7326/0003-4819-155-10-201111150-00376.
   PubMed Web of Science ®Google Scholar
• Wright TC, Jr, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144(1):51–56. doi: 10.1016/j.ygyno.2016.10.031.
   PubMed Web of Science ®Google Scholar
• Basoya S, Anjankar A. Cervical cancer: early detection and prevention in reproductive age group. Cureus. 2022;14(11):e31312. doi: 10.7759/cureus.31312.
   PubMed Web of Science ®Google Scholar
• Doorbar J, Egawa N, Griffin H, et al. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23. doi: 10.1002/rmv.1822.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. doi: 10.1016/S2214-109X(19)30482-6.
   PubMed Web of Science ®Google Scholar
• Liu G, Markowitz LE, Hariri S, et al. Seroprevalence of 9 human papillomavirus types in the United States, 2005-2006. J Infect Dis. 2016;213(2):191–198. doi: 10.1093/infdis/jiv403.
   PubMed Web of Science ®Google Scholar
• Coleman D, Day N, Douglas G, et al. European guidelines for quality assurance in cervical cancer screening. Europe against cancer programme. Eur J Cancer. 1993;29A(Suppl 4):S1–S38.
   PubMed Web of Science ®Google Scholar
• Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008;19(6):342–354. doi: 10.1111/j.1365-2303.2008.00623.x.
   PubMed Web of Science ®Google Scholar
• von Karsa L, Arbyn M, De Vuyst H, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31. doi: 10.1016/j.pvr.2015.06.006.
   Web of Science ®Google Scholar
• Wang W, Arcà E, Sinha A, et al. Cervical cancer screening guidelines and screening practices in 11 countries: a systematic literature review. Prev Med Rep. 2022;28:101813. doi: 10.1016/j.pmedr.2022.101813.
   PubMedGoogle Scholar
• European Commission: A cancer plan for Europe; [cited 2023 May]. Available from: https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/promoting-our-european-way-life/european-health-union/cancer-plan-europe_en
   Google Scholar
• Polman NJ, Snijders PJF, Kenter GG, et al. HPV-based cervical screening: rationale, expectations and future perspectives of the new Dutch screening programme. Prev Med. 2019;119:108–117. Feb doi: 10.1016/j.ypmed.2018.12.021.
   PubMed Web of Science ®Google Scholar
• Jeffrey DM, Vilalta A, Troeger KA. Revisiting the cost-effectiveness of HPV co-testing versus primary HPV testing for cervical cancer screening. J Women’s Health Dev. 2021;4:151–162.
   Google Scholar
• Vale DB, Silva MT, Discacciati MG, et al. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS One. 2021;16(5):e0251688. doi: 10.1371/journal.pone.0251688.
   PubMed Web of Science ®Google Scholar
• Denny L. Cytological screening for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):189–196. doi: 10.1016/j.bpobgyn.2011.08.001.
   PubMed Web of Science ®Google Scholar
• Wright TC, Jr, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):197–208. doi: 10.1016/j.bpobgyn.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Teixeira JC, Vale DB, Bragança JF, et al. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. BMC Public Health. 2020;20(1):576. doi: 10.1186/s12889-020-08688-4.
   PubMed Web of Science ®Google Scholar
• Asare M, Elizondo A, Dwumfour-Poku M, et al. Intervention to increase cervical cancer screening ­behavior among medically underserved women: effectiveness of 3R ­communication model. Healthcare (Basel). 2023;11(9):1323. doi: 10.3390/healthcare11091323.
   PubMedGoogle Scholar
• Wilailak S, Kengsakul M, Kehoe S. Worldwide initiatives to eliminate cervical cancer. Int J Gynaecol Obstet. 2021;155(Suppl 1):102–106. doi: 10.1002/ijgo.13879.
   PubMedGoogle Scholar
• Bogani G, Sopracordevole F, Ciavattini A, et al. Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV); the investigators of the Italian HPV study group (iHPV study group). Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023;32(6):525–532. doi: 10.1097/CEJ.0000000000000822.
   PubMed Web of Science ®Google Scholar
• Onuki M, Matsumoto K, Tenjimbayashi Y, et al. Human papillomavirus genotype and prognosis of cervical cancer: favorable survival of patients with HPV16-positive tumors. Papillomavirus Res. 2018;6:41–45. doi: 10.1016/j.pvr.2018.10.005.
   PubMedGoogle Scholar
• Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283(1):87–93. doi: 10.1001/jama.283.1.87.
   PubMed Web of Science ®Google Scholar
• Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46–52. doi: 10.1093/jnci/95.1.46.
   PubMedGoogle Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of ­human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a ­randomized controlled trial. Lancet Oncol. 2010;11:249–257.
   PubMed Web of Science ®Google Scholar
• Bulkmans NWJ, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–1772. doi: 10.1016/S0140-6736(07)61450-0.
   PubMed Web of Science ®Google Scholar
• Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials: international HPV screening working group. Lancet. 2014;383(9916):524–532.
   PubMed Web of Science ®Google Scholar
• Termrungruanglert W, Khemapech N, Tantitamit T, et al. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology. J Gyneco lOncol. 2019;30(2):e17. doi: 10.3802/jgo.2019.30.e17.
   PubMed Web of Science ®Google Scholar
• Burger EA, Kim JJ, Sy S, et al. Age of acquiring causal human papillomavirus (HPV) infections: leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clin Infect Dis. 2017;65(6):893–899. doi: 10.1093/cid/cix475.
   PubMed Web of Science ®Google Scholar
• Andersen B, Christensen BS, Christensen J, et al. HPV-prevalence in elderly women in Denmark. Gynecol Oncol. 2019;154:118–123. doi: 10.1016/j.ygyno.2019.04.680.
   PubMed Web of Science ®Google Scholar